BioNTech (BNTX) Q1 2026 earnings summary

Executive summary

• Accelerating late-stage oncology development with over 17 pivotal trial readouts targeted by 2030, focusing on high-incidence cancers such as lung, breast, and solid tumors, and leveraging novel combinations and multiple modalities including ADC, mRNA, and immunotherapy.

• Initiated five additional pivotal trials for pumitamig in collaboration with Bristol Myers Squibb in 2026, and announced a new independent company for next-generation mRNA innovations with leadership transition by end of 2026.

• Preparing for the 2026/2027 COVID-19 vaccine season with variant-adapted vaccines and ongoing commercial readiness.

Financial highlights

• Q1 2026 revenues were €118.1 million, down from €183 million year-over-year, mainly due to lower COVID-19 vaccine demand.

• Operating loss widened to €677.5 million (adjusted €640.2 million), and net loss increased to €532 million (IFRS) and €495 million (Adjusted).

• R&D expenses rose to €557 million (adjusted €527.1 million), and SG&A expenses increased to €151 million (adjusted €150.8 million).

• Cash, cash equivalents, and security investments totaled €16.8 billion as of March 31, 2026.

Outlook and guidance

• Reaffirmed full-year 2026 revenue guidance of €2.0–2.3 billion, with adjusted R&D expenses projected at €2.2–2.5 billion and SG&A at €700–800 million.

• Majority of COVID-19 vaccine revenue expected in the last four months of the year; BMS collaboration payment of €613 million to be recognized in Q3.

• Revenue stability expected from collaborations, pandemic preparedness contracts, and service businesses.

• Share repurchase program of up to $1.0 billion planned over the next twelve months; cost savings from manufacturing consolidation expected to reach €500 million annually by 2029.